You are here:
Home / Archives for AZN
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference
This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the year.
We [...]
Filed under Articles · Tagged with 2010 outlook, Akorn, AKRX, Amgen, AMGN, AnaptysBio, AstraZeneca, AZN, Bayer, BioLeap, biotechnology, BMY, Bristol-Myers Squibb Company, Cell Therapeutics, CEPH, Cephalon, Ception Therapeutics, Chiral Quest, CrystalGenomics, CTIC, CYCC, Cyclacel Pharmaceuticals, ENMD, EntreMed, FORMA Therapeutics, GDNF, glial cell line-derived neurotrophic factor, JP Morgan Healthcare Conference, KaloBios Pharmaceuticals, life sciences, MDCO, MDT, MedGenesis Therapeutix, Medicines Company, Medtronic, Novartis AG, NUVA, NuVasive, NVS, Peptimmune, Progentix Orthobiology, protein-protein interactions, Proteus Biomedical, roche, Rosetta Genomics, ROSG, Sanofi-Aventis, SNGX.OB, SNY, Soligenix, Trillium therapeutics, VentiRx Pharma, ZGEN, ZymoGenetics
Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other tactics. [...]
Filed under Articles · Tagged with Abelcet, activism, activist, Adagen, Alexander Denner, Alkermes, ALKS, AMLN, Amylin Pharmaceuticals, AstraZeneca plc, Avonex, AZN, BIIB, Biogen Idec, biotech, biotechnology, Biotechnology Value Fund, BMY, Bristol-Myers Squibb, Byetta, canfosfamide, Carl Icahn, cetuximab, DellaCamera Capital Management, DepoCyt, Eastbourne Capital Management, Eli Lilly, Eli Lilly & Co, EMIS, Emisphere Technologies, Endo Pharmaceuticals, ENDP, ENZN, Enzon Pharmaceuticals, Erbitux, EXEL, Exelixis, exenatide, Icahn Management, ImClone, interferon beta-1a, interferon beta-1b, LLY, Medarex, MedImmune, medx, multiple sclerosis, NASDAQ Biotechnology Index, NBI, Novartis AG, NVS, Oncaspar, Regeneron Pharmaceuticals, REGN, Richard Mulligan, shareholder activist, Telcyta, Telik, TELK, Third Point LLC
